Fact-checked by Grok 2 weeks ago

Prediabetes

Prediabetes is a serious health characterized by blood glucose levels that are higher than normal but not elevated enough to meet the diagnostic threshold for mellitus. It typically results from , where cells in the muscles, fat, and liver do not respond effectively to insulin, leading the to produce more insulin to compensate until it can no longer keep blood sugar levels in check. As a precursor to , prediabetes significantly increases the risk of developing the full disease, as well as cardiovascular complications such as heart disease and , if left unaddressed. In the United States, prediabetes affects approximately 98 million adults—more than one in three—making it a widespread concern, with over 80% of those affected unaware of their condition. The prevalence is higher among certain demographic groups, including older adults, racial and ethnic minorities such as , /Latinos, , , Pacific Islanders, and some , and those with a family history of . Without , people with prediabetes have a high risk of developing within five to ten years, underscoring the importance of early detection and lifestyle modifications to reverse or delay onset. The exact causes of prediabetes remain incompletely understood but are closely linked to a combination of genetic and environmental factors, including and sedentary behavior, which exacerbate . Key risk factors include being overweight or obese (particularly with excess abdominal fat), physical inactivity, age 35 or older, history of , (PCOS), smoking, and certain medications like glucocorticoids or antipsychotics. Most people with prediabetes experience no noticeable symptoms, though some may develop subtle signs such as increased thirst, , fatigue, , or darkened skin patches in areas like the neck or armpits (). Diagnosis of prediabetes is typically confirmed through blood tests, including an A1C test showing levels of 5.7% to 6.4%, a plasma glucose (FPG) test of 100 to 125 mg/dL, or an oral (OGTT) result of 140 to 199 mg/dL. Prevention and management focus on lifestyle interventions, such as losing 5% to 7% of body weight through a balanced and at least 150 minutes of moderate per week, which can reduce the risk of progressing to by up to 58% overall (and 71% in those over age 60). In select cases, medication like metformin may be prescribed, particularly for individuals at higher risk, alongside regular screening to monitor blood glucose levels.

Clinical Overview

Definition

Prediabetes is defined as an intermediate stage of in which blood glucose concentrations exceed normal levels but do not meet the diagnostic criteria for mellitus. This condition represents a high-risk state for progression to overt diabetes and is characterized by impaired insulin secretion, action, or both. According to the (ADA), prediabetes is diagnosed based on one or more of the following: fasting plasma glucose (FPG) of 100–125 mg/dL (5.6–6.9 mmol/L), 2-hour plasma glucose of 140–199 mg/dL (7.8–11.0 mmol/L during a 75-g oral (OGTT)), or A1c (HbA1c) of 5.7–6.4%. The (WHO) defines prediabetes, referred to as intermediate , through (IFG) with FPG of 110–125 mg/dL (6.1–6.9 mmol/L) or impaired glucose tolerance (IGT) with 2-hour OGTT values of 140–199 mg/dL (7.8–11.0 mmol/L), but does not recommend HbA1c for this classification. These thresholds distinguish prediabetes from normoglycemia—defined by ADA as FPG below 100 mg/dL (5.6 mmol/L), 2-hour OGTT below 140 mg/dL (7.8 mmol/L), and HbA1c below 5.7%—and from , which requires FPG of at least 126 mg/dL (7.0 mmol/L), 2-hour OGTT of at least 200 mg/dL (11.1 mmol/L), or HbA1c of at least 6.5%. The term "prediabetes" was coined by the ADA in 2003 to unify and raise awareness of the previously separate categories of IFG and IGT, emphasizing its role as a precursor to . Prediabetes is closely linked to , a cluster of conditions including central , , , and that collectively increase cardiovascular risk. Individuals with prediabetes often exhibit features of this syndrome, highlighting the shared of impaired glucose and cardiometabolic dysfunction.

Signs and Symptoms

Prediabetes is typically , meaning most individuals do not experience noticeable signs or symptoms and remain unaware of their condition until it is detected through routine blood glucose screening. This lack of overt manifestations contributes to the high prevalence of undiagnosed prediabetes, affecting an estimated 98 million adults alone. In rare cases, subtle symptoms may emerge that overlap with those of early , such as increased thirst (), frequent urination (), unexplained fatigue, and . These symptoms arise due to mild impairments in glucose regulation but are not specific to prediabetes and often go unrecognized or attributed to other causes like stress or . Certain associated skin and oral conditions can also signal underlying in prediabetes. , characterized by darkened, velvety patches of skin typically appearing on the neck, armpits, or , serves as a visible marker of . Additionally, gingival and early may be linked to prediabetic states, with studies showing a strong association between and increased , an indicator of chronic oral . However, prediabetes lacks unique symptoms exclusive to the condition; its discovery is primarily incidental through standard health evaluations rather than symptomatic presentation.

Etiology and Pathophysiology

Causes and Risk Factors

The primary causes of prediabetes involve a combination of and beta-cell dysfunction in the , which together impair the body's ability to regulate blood glucose levels effectively. occurs when cells in muscle, fat, and liver do not respond appropriately to insulin, reducing , while beta-cell dysfunction limits the and of insulin in response to rising blood sugar. This interplay leads to elevated blood glucose concentrations that characterize prediabetes, often progressing from or impaired glucose tolerance. Non-modifiable risk factors play a significant role in prediabetes susceptibility. Age 35 years or older increases risk due to age-related declines in insulin sensitivity and beta-cell function. A family history of diabetes, particularly type 2, elevates individual risk through shared genetic predispositions. Certain ethnic backgrounds confer higher susceptibility, including African American, Hispanic/Latino, American Indian, Alaska Native, Asian American, and populations, who experience disproportionate rates compared to non-Hispanic White individuals. Additionally, a history of during pregnancy substantially heightens the risk of developing prediabetes later in life. Certain medical conditions, such as (PCOS), , and Cushing’s syndrome, also increase risk. Modifiable risk factors are central to prediabetes prevention and include lifestyle and metabolic conditions that can be addressed. Overweight or obesity, defined as a body mass index (BMI) of 25 kg/m² or higher, promotes insulin resistance through excess adipose tissue, particularly visceral fat. Physical inactivity exacerbates this by further impairing glucose uptake in muscles. Poor dietary patterns, characterized by high intake of refined carbohydrates and saturated fats, contribute to weight gain and metabolic stress. Smoking is associated with increased oxidative stress and endothelial dysfunction, elevating prediabetes risk. Use of certain medications, such as glucocorticoids, antipsychotics, or HIV medications, can also contribute to risk. Hypertension and dyslipidemia, often co-occurring with obesity, compound insulin resistance through vascular and lipid abnormalities. Genetic factors influence prediabetes vulnerability, with variants in genes such as TCF7L2 ( 7-like 2) being among the strongest predictors. The rs7903146 polymorphism in TCF7L2 is linked to impaired beta-cell function and increased susceptibility to impaired glucose tolerance, independent of . These genetic markers explain a portion of familial clustering and ethnic disparities in risk. Environmental influences, particularly in low- and middle-income countries, contribute to rising prediabetes rates through rapid and associated sedentary lifestyles. Urban migration often leads to reduced , increased consumption of processed foods, and higher levels, amplifying metabolic risks in transitioning populations. Infrastructure limitations in these settings further hinder access to healthy environments, exacerbating the .

Pathophysiology

Prediabetes is characterized by peripheral , primarily in and , which impairs and disposal in response to insulin stimulation. This resistance arises from defects in insulin signaling pathways, such as reduced phosphorylation of insulin receptor substrate-1 (IRS-1) and Akt, leading to decreased translocation of glucose transporter 4 (GLUT4) to the cell membrane. In the early stages, pancreatic beta cells compensate for this resistance by increasing insulin secretion, resulting in that helps maintain euglycemia despite elevated postprandial glucose levels. Over time, sustained and chronic exposure to elevated glucose and free fatty acids lead to beta-cell exhaustion and dysfunction, marked by impaired glucose-stimulated insulin secretion and progressive loss of beta-cell mass. This exhaustion is exacerbated by glucolipotoxicity, which induces and endoplasmic reticulum stress in beta cells, ultimately reducing their ability to respond adequately to glucose challenges. Concurrently, alpha-cell dysregulation contributes to the , with inappropriate postprandial secretion that fails to suppress, promoting excessive hepatic glucose production and further elevating blood glucose levels. Chronic low-grade plays a key role in worsening , driven by proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 secreted from , which interfere with insulin signaling and promote . Alterations in the gut , including reduced abundance of beneficial genera like and , are associated with increased and low-grade , further impairing metabolic . Defects in hormones, particularly reduced secretion of (GLP-1) in response to oral glucose, diminish glucose-dependent insulin secretion and contribute to postprandial . The progression of prediabetes follows a continuum from normal glucose tolerance, through stages of (IFG) characterized by hepatic , to impaired glucose tolerance (IGT) involving peripheral defects, and ultimately to overt upon beta-cell failure. Risk factors such as can intensify peripheral by increasing ectopic lipid accumulation in muscle and liver.

Diagnosis and Screening

Diagnostic Criteria

Prediabetes is diagnosed based on specific thresholds for blood glucose levels or , as established by major health organizations. The (ADA) defines prediabetes using three primary tests: fasting plasma glucose (FPG) of 100–125 mg/dL (5.6–6.9 mmol/L), 2-hour plasma glucose of 140–199 mg/dL (7.8–11.0 mmol/L) during a 75-g oral (OGTT), or HbA1c of 5.7–6.4% (39–47 mmol/mol). These criteria remain consistent in the 2025 ADA Standards of Care, which emphasize HbA1c testing for its convenience—no fasting is required—and its reflection of average glycemia over 2–3 months, though with caveats for populations affected by conditions like or hemoglobinopathies where accuracy may be compromised. In contrast, the (WHO) criteria focus on (IFG) with FPG of 110–125 mg/dL (6.1–6.9 mmol/L) or impaired glucose tolerance (IGT) with 2-hour glucose of 140–199 mg/dL (7.8–11.0 mmol/L) during OGTT, but exclude HbA1c for prediabetes diagnosis due to insufficient evidence for its prognostic value in this context. The following table summarizes the key differences:
TestADA CriteriaWHO Criteria
Fasting Plasma Glucose (FPG)100–125 mg/dL (5.6–6.9 mmol/L)110–125 mg/dL (6.1–6.9 mmol/L)
2-hour OGTT140–199 mg/dL (7.8–11.0 mmol/L)140–199 mg/dL (7.8–11.0 mmol/L)
HbA1c5.7–6.4% (39–47 mmol/mol)Not used for diagnosis
Other tests, such as fasting insulin levels, are not standard for prediabetes diagnosis but may indicate underlying when elevated above 25 μU/mL, supporting further evaluation in or clinical contexts. Diagnosis typically requires confirmation with repeat testing on a subsequent day in individuals to rule out transient elevations, though a single abnormal result suffices if symptoms of are present. The OGTT is considered the gold standard for detecting prediabetes due to its ability to identify IGT more sensitively than FPG or HbA1c, but it is less practical for routine use owing to the need for fasting, standardized timing, and patient burden. Limitations of these tests include HbA1c inaccuracies in conditions such as , hemoglobinopathies, or rapid erythrocyte turnover, where it may overestimate or underestimate glycemia; in such cases, FPG or OGTT is preferred. Additionally, HbA1c detects fewer cases of prediabetes compared to OGTT, potentially missing early beta-cell dysfunction.

Screening Guidelines

Screening for prediabetes is recommended for adults aged 35 years and older, as well as younger adults with or (BMI ≥25 kg/m², or ≥23 kg/m² in individuals of Asian ancestry) and additional risk factors such as family history of diabetes, high-risk race or ethnicity, , or history of gestational diabetes mellitus (GDM). The (ADA) 2025 Standards of Care advise screening every three years for those with normal results, with more frequent testing if risk factors change, such as significant , and annual screening for individuals previously diagnosed with prediabetes (A1C 5.7–6.4%, , or impaired glucose tolerance). In alignment, the U.S. Preventive Services Task Force (USPSTF) recommends screening for prediabetes and in or obese adults aged 35–70 years, with referral to intensive interventions for those identified with prediabetes. High-risk populations warrant targeted screening protocols. Women with a history of GDM should be screened for prediabetes and 4–12 weeks postpartum using a 75-g oral , followed by screening every 1–3 years. Children and adolescents aged 10 years or older (or at the onset of ) who have (BMI ≥85th percentile) or (BMI ≥95th percentile) plus risk factors like family history or maternal GDM should also undergo screening. Additional groups include individuals initiating high-risk medications such as glucocorticoids or antipsychotics, with baseline testing and follow-up at 12–16 weeks, then annually; and people with , screened before and 3–6 months after starting antiretroviral therapy, then annually if normal, preferably using fasting plasma glucose due to A1C limitations in this population. Community and workplace screening programs facilitate broader access using point-of-care tests like HbA1c or fasting plasma glucose to identify at-risk individuals efficiently outside clinical settings. Globally, variations exist due to prevalence differences; the International Diabetes Federation (IDF) 2025 Diabetes Atlas emphasizes intensified screening in high-prevalence regions such as South-East Asia, including , where impaired glucose tolerance affects 13.8% of adults, to address the projected rise from 106.9 million cases in 2024 to 184.5 million by 2050. Early detection through screening enables interventions that reduce the risk of progression to by 58%, as demonstrated in the Diabetes Prevention Program lifestyle intervention.

Management and Prevention

Lifestyle Interventions

Lifestyle interventions form the cornerstone of managing prediabetes, focusing on sustainable behavioral changes to improve insulin sensitivity, promote , and reduce the risk of progression to . These approaches emphasize a combination of dietary modifications, increased , structured behavioral support, and adequate , which have been shown to be more effective than pharmacological options alone in high-risk individuals. Comprehensive programs like the Diabetes Prevention Program (DPP) model integrate these elements to achieve clinically meaningful outcomes. A primary goal of interventions is to achieve a 5–7% reduction in body weight, which can be accomplished through moderate tailored to individual needs, typically 1,200–1,500 kcal/day for women and 1,500–1,800 kcal/day for men, combined with portion control and nutrient-dense food choices. This level of enhances glycemic control and delays onset without requiring extreme measures. In the DPP, participants targeted at least a 7% weight reduction through such strategies, resulting in sustained benefits over time. Physical activity recommendations include at least 150 minutes per week of moderate-intensity , such as brisk walking, distributed across most days, supplemented by resistance training 2–3 days per week to build muscle mass and improve metabolic health. These guidelines help counteract sedentary behaviors common in prediabetes and support long-term adherence when personalized to the individual's fitness level. Dietary patterns should prioritize whole foods, with evidence supporting Mediterranean-style diets rich in , fruits, whole grains, lean proteins, and healthy fats like , which improve glycemic control and reduce . Low-glycemic index diets, emphasizing foods that minimize blood sugar spikes, also aid in and insulin sensitivity by focusing on fiber-rich options while limiting refined sugars and processed foods. Both patterns align with broader nutritional consensus for prediabetes, promoting balanced macronutrients over restrictive regimens. The 2025 (ADA) Standards of Care emphasize as a central component of prediabetes , recommending 7–9 hours of quality per night and addressing disorders like , as poor can worsen . Behavioral strategies are essential for long-term success, drawing from the DPP model of intensive coaching delivered through a 16-session over 24 weeks, followed by ongoing group or individual support. Techniques include goal-setting, of and activity via diaries or logs, problem-solving for barriers, and to foster habit formation. These structured approaches enhance participant engagement and retention. The efficacy of these interventions is well-established by the landmark DPP study, which demonstrated a 58% reduction in diabetes incidence over 3 years among participants with prediabetes who underwent intensive changes compared to placebo. This benefit persisted in long-term follow-up, underscoring the durability of modifications. The 2025 American Diabetes Association (ADA) Standards of Care incorporate updates emphasizing the integration of digital tools, such as mobile apps for tracking progress and wearables for real-time activity and glucose monitoring, to improve adherence and personalize coaching in prediabetes management. These technologies support virtual delivery of DPP-style programs, making interventions more accessible.

Pharmacological and Other Therapies

Pharmacological therapies for prediabetes are recommended as an adjunct to interventions when the latter alone are insufficient to achieve glycemic control, particularly in individuals with elevated HbA1c levels (≥6.0%). The American Diabetes Association's 2025 Standards of Care endorse metformin as the primary option for high-risk adults, defined as those with ≥35 kg/m², aged 25–59 years, fasting glucose ≥110 mg/dL, HbA1c ≥6.0%, or a history of gestational diabetes mellitus. Metformin, a , is considered first-line for preventing progression to in these high-risk groups due to its established safety profile and efficacy. In the Diabetes Prevention Program Outcomes Study (DPPOS), metformin reduced the incidence of by 31% compared to over an average follow-up of 2.8 years, with sustained benefits in subgroups such as younger individuals and those with higher . Long-term data from DPPOS further indicate a 34% risk reduction at 10 years in high-risk participants. However, metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of lactic acidosis, and monitoring for vitamin B12 deficiency is advised with prolonged use. Other agents, such as glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide), are used off-label in prediabetes primarily for weight loss in obese individuals, showing reductions in diabetes incidence over 3 years compared to placebo. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are under active investigation for prediabetes, with emerging evidence suggesting they improve metabolic parameters and reduce progression to type 2 diabetes in high-risk populations (hazard ratio 0.62). For individuals with severe obesity (BMI ≥35 kg/m²), bariatric surgery offers a therapeutic option that can reverse prediabetes in 60–80% of cases through substantial weight loss and metabolic improvements. Routine use of vaccinations or general supplements is not recommended for prediabetes management; however, vitamin D supplementation may be considered in cases of confirmed deficiency, as it has been associated with a modest reduction in diabetes risk among prediabetic individuals (risk reduction of 10–13%).

Outcomes and Public Health

Prognosis and Remission

Prediabetes represents a critical window in the natural history of glucose dysregulation, where individuals face a variable risk of progressing to or reverting to normoglycemia. The annual progression rate from prediabetes to is typically 5–10% in general populations. However, this rate can escalate significantly in untreated high-risk groups, with up to 50% progressing within 5 years due to factors such as obesity and impaired glucose tolerance. Remission of prediabetes is defined as a sustained return to normoglycemia, characterized by HbA1c below 5.7%, fasting plasma glucose under 100 mg/dL, or a 2-hour oral glucose tolerance test result below 140 mg/dL, maintained for at least 1 year without glucose-lowering medications. Spontaneous remission occurs frequently, with rates up to 50% in some cohorts over 2-3 years, often linked to early detection and minimal beta-cell impairment. Intensive lifestyle interventions can achieve remission rates around 40%, as evidenced by long-term follow-up in the . Several factors influence the prognosis of prediabetes, including the duration of the condition, preserved beta-cell function, and success in achieving weight loss. Longer duration of prediabetes correlates with diminished beta-cell reserve and higher progression risk, whereas early weight loss of 5–7% body weight enhances insulin sensitivity and supports remission. Recent insights from a 2025 Lancet study on monitored cohorts indicate that reversion to normoglycemia occurs more frequently than progression to type 2 diabetes, with a 10-year probability of progression at 12.5% compared to higher reversion rates in followed individuals. If left untreated, prediabetes elevates cardiovascular risk by 13% to 30% compared to normoglycemic individuals, driven by endothelial dysfunction and subclinical inflammation. Lifestyle interventions, as detailed in management guidelines, promote remission by addressing these modifiable risks.

Epidemiology

Prediabetes represents a significant public health challenge, with global prevalence estimated at approximately 8–10% among adults aged 20–79 years, affecting around 464 million individuals as of 2021 modeling. Updated estimates for 2024 indicate a rising burden, with 12.0% of adults (634.8 million) having impaired glucose tolerance (IGT) and 9.2% (487.7 million) having impaired fasting glucose (IFG), though overlap exists between these categories. Projections suggest substantial growth, potentially reaching 850 million cases by 2045, driven by population aging and lifestyle factors. In the United States, prediabetes affects approximately 98 million adults aged 18 years or older, representing about 38% of the adult population based on 2021 data from the National Health and Nutrition Examination Survey (NHANES), with similar figures persisting into 2023–2025 Behavioral Risk Factor Surveillance System (BRFSS) analyses. As of 2023, an estimated 32.7% of U.S. adolescents aged 12-17 years (8.4 million) have prediabetes, underscoring increases among younger populations. Regional variations are pronounced globally; for instance, IGT prevalence is highest in the North America and Caribbean region at 13.1%, while IFG is most prevalent in Southeast Asia at 9.4%, with lower rates in Europe (IGT 10.1%, IFG 5.9%) and the Western Pacific (IFG 3.4%). In the Middle East and North Africa, combined prediabetes rates reach 15–20%, reflecting higher overall hyperglycemia burdens compared to Europe's 6–8%. Prevalence trends are upward globally, largely attributable to the obesity epidemic, with adult obesity rates more than doubling since 1990 and continuing to rise, exacerbating insulin resistance. The U.S. Centers for Disease Control and Prevention (CDC) in 2025 highlighted the need for scalable public health interventions to curb this trajectory, as prediabetes cases have stabilized at around one-third of U.S. adults but show increases among younger populations. Demographic disparities amplify the burden, with higher rates among low-income groups due to limited access to healthy foods and healthcare, and in urban areas where sedentary lifestyles prevail, though rural-urban differences vary by metric. Sex differences are minimal overall, but gestational prediabetes—often manifesting as hyperglycemia in pregnancy—affects 10–20% of pregnancies worldwide, particularly in low- and middle-income countries. Underdiagnosis remains a critical issue, with up to 90% of individuals globally unaware of their prediabetes status due to its asymptomatic nature and insufficient screening, leading to delayed interventions and higher progression risks. This unawareness is especially prevalent in low-resource settings, underscoring the urgency for enhanced global surveillance.

Research Directions

Emerging Diagnostics

Continuous glucose monitoring (CGM) devices provide real-time data on interstitial glucose levels, enabling the detection of postprandial glucose spikes that may not be captured by traditional fasting or HbA1c tests. These spikes, often exceeding 140 mg/dL in individuals with normal fasting glucose, have been linked to early insulin resistance and increased risk of progression to prediabetes. A 2025 study published in Nature Medicine demonstrated that an AI-enhanced CGM model could identify hidden diabetes risk in normoglycemic individuals by analyzing glucose variability patterns alongside microbiome and dietary factors, achieving early detection in at-risk populations before standard diagnostic thresholds are met. Similarly, clinical trials in 2025 have shown CGM's utility in revealing glycemic excursions in non-diabetic adults, with time above range metrics (>140 mg/dL) serving as predictors of future prediabetes, even when average glucose remains normal. Emerging biomarkers from profiling offer insights into pre-prediabetes states by identifying metabolic perturbations prior to overt glucose dysregulation. Branched-chain (BCAAs), such as , , and , have been consistently elevated in individuals progressing to prediabetes, reflecting impaired insulin signaling and beta-cell dysfunction. A 2025 confirmed that circulating BCAA levels rise significantly in prediabetes compared to normoglycemia, with odds ratios indicating a strong association (OR 1.45–2.10 per standard deviation increase), positioning BCAAs as potential early warning indicators measurable via targeted plasma assays. Other metabolomic signatures, including reduced and lysophosphatidylcholines, further delineate this transitional phase, as validated in longitudinal cohorts where these changes preceded prediabetes by up to 5 years. Polygenic risk scores (PRS) aggregate hundreds of genetic variants to quantify hereditary to prediabetes, enhancing risk stratification beyond monogenic approaches. Developed from genome-wide studies, these scores incorporate loci related to beta-cell function and insulin sensitivity, with a 2025 analysis showing that a one standard deviation increase in PRS correlates with a 37% higher likelihood of developing prediabetes over 10 years in multi-ancestry cohorts. Trans-ancestry PRS models, refined in 2025, improve predictive performance across diverse populations, identifying high-risk individuals with normal glucose levels for targeted monitoring. When combined with clinical factors, PRS can enhance risk prediction, underscoring their role in early genetic screening. Artificial intelligence (AI) integrated with wearable devices analyzes multimodal data from accelerometers, sensors, and CGM to predict prediabetes onset with high accuracy. algorithms process patterns in , , and glucose fluctuations to forecast risk, with 2025 trials reporting prediction accuracies exceeding 80% ( 0.82–0.89) in normoglycemic adults followed for 2–5 years. For instance, models using smartwatch-derived inertial data alongside CGM have detected prediabetes in unconstrained settings, emphasizing reduced activity and nocturnal glucose rises as key precursors. These tools facilitate non-invasive, continuous , with validation in large cohorts confirming superior performance over traditional models. Refinements to the oral (OGTT) aim to shorten protocols while maintaining diagnostic , addressing the burden of the standard 2-hour procedure. Abbreviated versions focusing on 1-hour post-load glucose (1-h PG) levels have emerged as efficient alternatives, with a 2025 study establishing a 120 mg/dL threshold that predicts progression from normoglycemia to prediabetes with 61% and 67% specificity. These protocols reduce testing time to 60–90 minutes, correlating strongly with insulin indices and enabling earlier identification in population screening. Research from UT Health in 2025 has defined a "pre-prediabetes" stage characterized by subclinical detectable via dynamic metrics before standard glucose thresholds are breached. Using hyperinsulinemic-euglycemic clamps and oral minimal model assessments, investigators found that individuals with 1-h PG of 120–155 mg/dL exhibit elevated hepatic (HIRI >30%) and reduced beta-cell responsivity, increasing cardiometabolic risk by 2–3 fold compared to those below this range. This stage, observed in 15–20% of normoglycemic adults in longitudinal data, precedes prediabetes by 3–7 years and is associated with adverse lipid profiles and inflammation, advocating for insulin sensitivity-focused interventions at this juncture.

Prevention and Reversal Strategies

Ongoing research into prediabetes prevention and reversal emphasizes innovative therapeutic strategies beyond traditional modifications, focusing on biological mechanisms to halt progression to . Remission-focused clinical trials have highlighted the potential for weight-independent reversal through recovery of β-cell function, as demonstrated in a 2025 from published in The Lancet Diabetes & Endocrinology, which linked β-cell regeneration to sustained normoglycemia in prediabetic individuals without significant . Preclinical investigations further support this approach, with harmine-based compounds showing promise in inducing human β-cell and mass expansion and in animal models, potentially offering a novel pathway for reversal independent of caloric restriction. Public health initiatives are advancing scalable community-based programs to prevent prediabetes progression, particularly in high-risk populations affected by . The U.S. Centers for Disease Control and Prevention (CDC) in 2025 outlined expanded strategies incorporating delivery for interventions targeting dietary patterns and reduction, enabling broader access in underserved communities through virtual coaching and monitoring tools. These programs build on evidence from digital platforms, where AI-powered variants achieved comparable risk reduction to in-person sessions, with participants demonstrating improved glycemic control and over 12 months. Pharmacological innovations, particularly dual GLP-1/GIP receptor agonists like , are demonstrating superior efficacy in achieving prediabetes remission compared to single-agonist therapies. Phase 3 trials, including the SURMOUNT-1 extension reported in 2025, showed reduced the incidence of progression to by over 90% over three years in prediabetic individuals with , with only 1.3% of treated participants progressing versus 13.3% on . This effect is attributed to enhanced insulin sensitivity and β-cell preservation, positioning as a leading candidate for preventive despite its primary approval for and . Emerging microbiome-targeted interventions offer another frontier for prediabetes reversal by modulating the gut-insulin axis to improve metabolic . Early human studies have reported promising outcomes with modulation to enhance insulin sensitivity and reduce inflammatory markers in prediabetic subjects. At the policy level, the Diabetes Federation (IDF) in its 2025 Global Clinical Practice Recommendations advocates for integrated prevention strategies in high-burden regions, emphasizing community-wide interventions to address socioeconomic drivers of prediabetes. These include school-based programs to promote healthy eating and from childhood, with global surveys revealing that such policies in over 50 countries have increased early screening and reduced rates by 10-20% in targeted populations. As of November 2025, ongoing FDA reviews consider expanded CGM access for non-diabetics, potentially enhancing early prediabetes detection through wearables. Despite these advances, significant challenges persist in translating into clinical practice, including the absence of FDA-approved pharmacological agents specifically for prediabetes treatment, limiting options to in high-risk subgroups such as those with or family history. efforts are thus prioritizing personalized approaches for these subgroups, where genetic and metabolic may enhance , though long-term data remain a barrier to widespread adoption. While established interventions remain the cornerstone of prediabetes management, as detailed in prior sections, novel strategies like those discussed here aim to complement them for more durable remission.

References

  1. [1]
    Prediabetes – Your Chance to Prevent Type 2 Diabetes - CDC
    May 15, 2024 · Prediabetes is a serious health condition that increases your risk of developing type 2 diabetes, heart disease, and stroke.
  2. [2]
    Insulin Resistance & Prediabetes - NIDDK
    When your blood glucose levels get higher than normal but not high enough to be diagnosed as diabetes, you have prediabetes. Researchers don't fully understand ...
  3. [3]
    Prediabetes: Could It Be You? Infographic | Diabetes - CDC
    With prediabetes, your blood sugar levels are higher than normal, but not high enough yet to be diagnosed as type 2 diabetes. Prediabetes risks. Prediabetes ...What To Know · Graphic Text · Prediabetes -- Could It Be...Missing: definition causes<|control11|><|separator|>
  4. [4]
    Prediabetes - Symptoms and causes
    ### Summary of Prediabetes from Mayo Clinic (https://www.mayoclinic.org/diseases-conditions/prediabetes/symptoms-causes/syc-20355278)
  5. [5]
    2. Diagnosis and Classification of Diabetes: Standards of Care in ...
    Dec 11, 2023 · Prediabetes is the term used for individuals whose glucose or A1C levels do not meet the criteria for diabetes yet have abnormal carbohydrate ...Diagnostic Tests for Diabetes · Classification · Prediabetes and Type 2...
  6. [6]
    Definition and diagnosis of diabetes mellitus and intermediate ...
    Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation 21 April 2006.
  7. [7]
    Prediabetes - Endotext - NCBI Bookshelf - NIH
    Mar 3, 2022 · According to the ADA and EASD, the diagnosis of prediabetes is made when the fasting plasma glucose (FPG) is 100-125 mg/dl (5.6-6.9 mmol/l; “ ...SCREENING · DIAGNOSIS · RISK FOR DIABETES · COMPLICATIONS OF...
  8. [8]
    Pre-Diabetes and What It Means: The Epidemiological Evidence
    Prediabetes is an intermediate stage between normal glycemia and diabetes and is highly prevalent, especially in older age groups and obese individuals.Epidemiology · Defining Prediabetes · Risk Of Diabetes Or...
  9. [9]
    The Metabolic Syndrome: Time for a Critical Appraisal | Diabetes Care
    Sep 1, 2005 · The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of ...
  10. [10]
    Prediabetes: What Is It, Causes, Symptoms & Treatment
    Healthy blood sugar (glucose) levels are 70 to 99 milligrams per deciliter (mg/dL). If you have undiagnosed prediabetes, your levels are typically 100 to 125 mg ...Symptoms And Causes · Management And Treatment · Living With<|separator|>
  11. [11]
    Prediabetes - StatPearls - NCBI Bookshelf - NIH
    Prediabetes is a precursor before the diagnosis of diabetes mellitus. Adults with prediabetes often may show no signs or symptoms of diabetes but will have ...
  12. [12]
    Potential association between prediabetic conditions and gingival ...
    IFG and/or prediabetes are strongly associated with BOP, a marker of chronic gingival/periodontal inflammation.
  13. [13]
    About Insulin Resistance and Type 2 Diabetes - CDC
    May 14, 2024 · Insulin resistance leads to prediabetes and type 2 diabetes. · Find out more about what it is, what causes it, and how you can reverse it.Key Points · What Is Insulin? · What Is Insulin Resistance?<|separator|>
  14. [14]
    Beta Cell Dysfunction and Insulin Resistance - PMC - PubMed Central
    Beta cell dysfunction supersedes insulin resistance in inducing diabetes. Both pathological states influence each other and presumably synergistically ...
  15. [15]
    Differential role of insulin resistance and β-cell function in the ...
    Mar 5, 2019 · ... insulin resistance and β-cell dysfunction were the determinant of developing prediabetes and diabetes, respectively. Insulin resistance is a ...
  16. [16]
    Diabetes Risk Factors - CDC
    May 14, 2024 · Prediabetes and type 2 diabetes · Have overweight or obesity. · Are age 45 or older. · Have a parent or sibling with type 2 diabetes. · Are ...Prediabetes · Diabetes and Polycystic Ovary... · Diabetes and Men
  17. [17]
    The Surprising Truth About Prediabetes | Diabetes - CDC
    May 15, 2024 · Prediabetes is a serious health condition. People with prediabetes have higher blood sugar than normal, but not high enough yet for a diabetes diagnosis.Missing: definition | Show results with:definition
  18. [18]
    Prediabetes Doubles in Adolescents, Key Risk for Older Adults
    Aside from initial A1C and higher body mass index, a family history of diabetes was another key predictor. Interestingly, progression to diabetes was similar ...Missing: factors | Show results with:factors
  19. [19]
    Diabetes Prevention | ADA
    The two share some risk factors, such as age, gender and ethnicity, and lifestyle factors.
  20. [20]
    Modifiable risk factors associated with prediabetes in men and women
    Jan 22, 2015 · The modifiable risk factors included were: smoking habit, alcohol consumption, low physical activity, inadequate diet, hypertension, ...
  21. [21]
    The TCF7L2 Locus: A Genetic Window Into the Pathogenesis ... - NIH
    Although TCF7L2 is by far not the only locus associated with type 2 diabetes, it does represent one of the first and strongest genetic signals for this trait.
  22. [22]
    The rs7903146 Variant in the TCF7L2 Gene Increases the Risk of ...
    Jun 13, 2017 · The rs7903146 variant in the TCF7L2 gene increases the risk of IGT/T2D in obese adolescents by impairing β-cell function, and hepatic insulin sensitivity ...
  23. [23]
    [PDF] Epidemiological status of type 2 diabetes mellitus in the Middle East ...
    environmental risk factors such as air pollution and non- optimal ... In low- and middle-income countries, infrastructure is inadequate to support ...<|control11|><|separator|>
  24. [24]
    The growing burden of diabetes in Viet Nam
    Apr 7, 2016 · In Viet Nam, the prevalence of diabetes is growing at alarming rates and has almost doubled within the past 10 years.
  25. [25]
    Prediabetes Deserves More Attention: A Review - PMC
    The pathophysiologic defects underlying prediabetes include insulin resistance, β-cell dysfunction, increased lipolysis, inflammation, suboptimal incretin ...<|control11|><|separator|>
  26. [26]
  27. [27]
    Impaired Suppression of Glucagon in Obese Subjects Parallels ...
    In individuals with prediabetes, an increased glucagon response to arginine challenge has been shown to predict the development of T2D (15).
  28. [28]
  29. [29]
    Aberrant intestinal microbiota in individuals with prediabetes - PMC
    Collectively, our data show that individuals with prediabetes have aberrant intestinal microbiota characterised by a decreased abundance of the genus ...
  30. [30]
    GLP-1 Response to Oral Glucose Is Reduced in Prediabetes ...
    Feb 12, 2015 · Our findings indicate that a reduction in GLP-1 response to oral glucose occurs prior to the development of type 2 diabetes and obesity.
  31. [31]
    2. Diagnosis and Classification of Diabetes: Standards of Care in ...
    Dec 9, 2024 · ... prediabetes defined by A1C criteria (5–8). The same tests may be used to screen for and diagnose diabetes and to detect individuals with ...Diagnostic Tests for Diabetes · Classification<|control11|><|separator|>
  32. [32]
    Diagnostic Criteria and Classification of Hyperglycaemia First ... - NCBI
    Recommendation 2 · fasting plasma glucose ≥ 7.0 mmol/l (126 mg/ dl) · 2-hplasma glucose ≥ 11.1 mmol/l (200 mg/dl) following a 75g oral glucose load · random plasma ...
  33. [33]
    Identifying prediabetes using fasting insulin levels - PubMed
    At a fasting insulin level > 9.0 microIU/mL, prediabetes would be correctly identified in 80% of affected patients.
  34. [34]
    Screening for Prediabetes and Type 2 Diabetes in Children and ...
    Sep 13, 2022 · The diagnosis of prediabetes or type 2 diabetes should be confirmed with repeat testing before starting interventions. Screening Tests.<|control11|><|separator|>
  35. [35]
    Oral glucose tolerance testing - RACGP
    The oral glucose tolerance test (OGTT) is currently the gold standard for the diagnosis of diabetes. The recommended preparation for and administration of ...
  36. [36]
    HbA1c for the Diagnosis of Diabetes and Prediabetes - NIH
    Limitations are that only single measurements of HbA1c and FPG were performed and there was no measurement of 2-h post-glucose load glucose levels. The latter ...
  37. [37]
    Prediabetes and Type 2 Diabetes: Screening - uspstf
    Aug 24, 2021 · A fasting plasma glucose level of 126 mg/dL (6.99 mmol/L) or greater, an HbA1c level of 6.5% or greater, or a 2-hour postload glucose level of ...
  38. [38]
    [PDF] 11th Edition | 2025 - Diabetes Atlas
    The global prevalence of intermediate hyperglycaemia is substantial, although there is no consensus definition for intermediate states of hyperglycaemia or ...<|control11|><|separator|>
  39. [39]
    Reduction in the Incidence of Type 2 Diabetes with Lifestyle ...
    The incidence of diabetes was reduced by 58 percent with the lifestyle intervention and by 31 percent with metformin, as compared with placebo.
  40. [40]
    3. Prevention or Delay of Diabetes and Associated Comorbidities
    Dec 9, 2024 · The two major goals of the DPP intensive lifestyle intervention were to achieve and maintain a minimum of 7% weight loss and to partake in 150 ...
  41. [41]
    Metformin for diabetes prevention: insights gained ... - PubMed Central
    After an average follow-up of 2.8 years, metformin reduced the incidence of diabetes by 31 % compared with placebo, with a greater effect in those who were more ...
  42. [42]
    Warning use metformin in certain patients with reduced kidney function
    Apr 8, 2016 · Metformin is contraindicated in patients with an eGFR below 30 mL/minute/1.73 m2. Starting metformin in patients with an eGFR between 30-45 ...
  43. [43]
    Current Evidence on SGLT-2 Inhibitors in Prediabetes - PubMed
    Apr 10, 2025 · A growing body of evidence has shown the beneficial effects of sodium-glucose transporter 2 (SGLT-2) inhibitors in prediabetes.Missing: investigation | Show results with:investigation
  44. [44]
    Sodium–glucose cotransporter 2 inhibitors reduce the risk of ...
    Aug 7, 2024 · The analysis of patients with prediabetes found that SGLT2is further reduced incident T2D [HR 0.62 (95% CI 0.45, 0.80)].
  45. [45]
    Bariatric surgery and diabetes remission: Who would have thought it?
    Additionally, bariatric surgery is associated with improvements or remission of diabetes in up to 80%, and reduction in incidental diabetes by 73%, apart from ...
  46. [46]
    Effects of Vitamin D Supplementation on Prevention of Type 2 ...
    Jun 11, 2020 · In persons with prediabetes, vitamin D supplementation reduces the risk of T2DM and increases the reversion rate of prediabetes to normoglycemia.Introduction · Methods · Results · Discussion
  47. [47]
    Vitamin D Supplementation for Prevention of Type 2 Diabetes Mellitus
    Vitamin D supplementation, when compared with placebo, reduced the risk of developing diabetes by 10% to 13% in persons with prediabetes not selected for ...Abstract · Review Strategy and Literature... · Evidence Synthesis and Next...
  48. [48]
    Prediabetes: A high-risk state for developing diabetes - PMC
    Jan 14, 2014 · Progression from prediabetes to diabetes. Around 5–10% of people with prediabetes become diabetic annually although conversion rate varies by ...
  49. [49]
    Global Prevalence of Prediabetes | Diabetes Care
    May 17, 2023 · ... at high risk for developing diabetes, with up to 50% progressing to diabetes within 5 years (5). People with IFG or IGT are also at elevated ...
  50. [50]
    Special Article: Remission of Type 2 Diabetes
    Diabetes complete remission was defined as an A1C below 5.7% without any medications for at least 1 year. Partial remission was achieved if a participant ...
  51. [51]
    Regression from prediabetes to normal glucose levels is more ... - NIH
    Aug 26, 2019 · After 2.2 years of follow-up, in those with prediabetes, the cumulative incidence of regression to euglycemia ranged between 31.4% and 68.9%, ...
  52. [52]
    Prediabetes Remission for Type 2 Diabetes Prevention | DZD
    Jul 18, 2024 · The studies showed that in some patients with prediabetes (~40%), weight loss (≥5% of original body weight) led to prediabetes remission.
  53. [53]
    Prediabetes remission to reduce the global burden of type 2 diabetes
    Feb 14, 2025 · This review examines the current definition and global prevalence of prediabetes and evaluates the potential of prediabetes remission to reduce the alarming ...
  54. [54]
    Role of weight loss-induced prediabetes remission in the prevention ...
    May 23, 2024 · Remission rates increased with increasing weight loss. Thus, weight loss is an important driver of prediabetes remission and, in PLIS, an ...
  55. [55]
    Association between prediabetes and risk of cardiovascular disease ...
    Nov 23, 2016 · Prediabetes, defined as impaired glucose tolerance, impaired fasting glucose, or raised HbA 1c, was associated with an increased risk of cardiovascular disease.Missing: untreated | Show results with:untreated<|control11|><|separator|>
  56. [56]
    Obesity and overweight - World Health Organization (WHO)
    May 7, 2025 · In 2022, 1 in 8 people in the world were living with obesity. Worldwide adult obesity has more than doubled since 1990, and adolescent ...
  57. [57]
    Public Health Research and Program Strategies for Diabetes ... - CDC
    Mar 20, 2025 · Since then, largely because of substantial increases in obesity, the prevalence of diabetes in the US has more than doubled, now nearing 12% of ...
  58. [58]
    Social Determinants of Health and Diabetes: A Scientific Review
    Nov 2, 2020 · Decades of research have demonstrated that diabetes affects racial and ethnic minority and low-income adult populations in the U.S. ...
  59. [59]
    Urban–Rural Differences in the Prevalence of Diabetes Among ...
    May 3, 2024 · Urban areas continue to have a high prevalence of diabetes and prediabetes; rural areas depict a much higher prevalence of prediabetes than ...
  60. [60]
    Sex-Based Differences in Diabetes Prevalence and Risk Factors
    Sep 24, 2019 · In the present study, a significant, sex-based difference in the prevalence of DM within this low-income population was not observed.
  61. [61]
    IDF Diabetes Atlas: Estimation of Global and Regional Gestational ...
    Dec 6, 2021 · Results: The pooled global standardized prevalence of GDM was 14.0% (95% confidence interval: 13.97-14.04%). The regional standardized ...Missing: prediabetes | Show results with:prediabetes
  62. [62]
    AI model detects hidden diabetes risk by reading glucose spikes
    Jul 31, 2025 · The new model, described in Nature Medicine on July 31, 2025, uses continuous glucose monitor (CGM) data alongside gut microbiome, diet, ...
  63. [63]
    Continuous Glucose Monitoring for Prediabetes: Roles, Evidence ...
    Continuous glucose monitoring (CGM) has transformed the care of patients with diabetes, and there is great potential to extend these benefits to prediabetes.
  64. [64]
    Association of circulating branched-chain amino acids with risk ... - NIH
    Sep 25, 2025 · Conclusions. This meta-analysis supports the hypothesis that circulating BCAA levels increase in PreDM, suggesting that measuring BCAA levels ...
  65. [65]
    Novel biomarkers for pre‐diabetes identified by metabolomics
    Three novel metabolites, glycine, LPC (18:2) and C2, were identified as pre‐diabetes‐specific markers. Their changes might precede other branched‐chain and ...
  66. [66]
    Genetic risk and polygenic risk score assessment of prediabetes ...
    Jun 5, 2025 · For the top-performing PGS, each standard deviation increase in the score was associated with a ~37% higher likelihood of developing prediabetes ...
  67. [67]
    Polygenic risk score for type 2 diabetes shows context-dependent ...
    Oct 1, 2025 · Polygenic risk scores hold prognostic value for identifying individuals at higher risk of type 2 diabetes. However, further characterization ...
  68. [68]
    Genetic risk and polygenic risk score assessment of prediabetes ...
    Jun 5, 2025 · Abstract. Aims: To identify susceptibility loci to prediabetes and evaluate the performance of existing polygenic risk scores (PGS) for type 2 ...
  69. [69]
    Continuous glucose monitoring combined with artificial intelligence
    May 25, 2025 · This early diagnostic strategy based on CGM and AI not only enhances diagnostic accuracy but also enables personalized assessment of diabetes ...
  70. [70]
    Prediabetes detection in unconstrained conditions using wearable ...
    This research explores the feasibility of using wearable continuous glucose monitoring along with smartwatches with embedded inertial sensors.Missing: trials | Show results with:trials
  71. [71]
    AI and Wearable Tech can Predict Diabetes Risk Before Symptoms
    Aug 7, 2025 · Discover how new AI can spot hidden diabetes risk earlier than ever before. Keep reading for the full story.
  72. [72]
    One-Hour Plasma Glucose Predicts the Progression From Normal ...
    May 16, 2025 · The 1-h PG was the strongest predictor of developing prediabetes, and a 1-h cut point of 120 mg/dL had 61% sensitivity and 67% specificity.
  73. [73]
    Oral glucose tolerance test in diabetes, the old method revisited - PMC
    It has been widely suggested in recent years that the duration of the OGTT should be shortened to use the 30-min or 1hPG. The glucose level obtained from a ...Missing: abbreviated | Show results with:abbreviated
  74. [74]
    UT San Antonio Health Science Center scientists pinpoint early ...
    Sep 11, 2025 · 11, 2025 – A study from The University of Texas at San Antonio Health Science Center indicates that changes in the body that lead to Type 2 ...
  75. [75]
    Insulin Resistance Is Associated With Cardiometabolic Risk in ...
    May 1, 2025 · Objective: This work aims to examine if insulin resistance (IR) is associated with markers of glycemic, cardiometabolic, and atherosclerotic ...
  76. [76]
    The central role of recovery of β-cell function in the remission of ...
    The central role of recovery of β-cell function in the remission of prediabetes: a prospective cohort study in Canada. Lancet Diabetes Endocrinol. 2025 Oct;13( ...
  77. [77]
    Drug-induced regeneration of pancreatic beta cells: An approach to ...
    Sep 6, 2025 · This unexpected result suggests that compounds like harmine, 2 ... (2025) Advances in cell replacement therapies for diabetes. Diabetes ...
  78. [78]
    AI-Powered Diabetes Prevention Program Shows Similar Benefits to ...
    Oct 27, 2025 · ... 58% less likely to develop type 2 diabetes, as shown in the CDC's original Diabetes Prevention Program (DPP) clinical study. However, access ...
  79. [79]
    Tirzepatide for Obesity Treatment and Diabetes Prevention
    Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both ...
  80. [80]
    Tirzepatide Shows Powerful Diabetes-PreventionEffect in Three ...
    Oct 19, 2025 · Only 1.3% of participants receiving Tirzepatide progressed to type 2 diabetes after 176 weeks of treatment, compared to 13.3% in the placebo ...
  81. [81]
    Fecal microbiota transplant (FMT) versus metformin in type 2 ...
    Sep 14, 2025 · We examined the mechanisms through which Metf and FMT influence gut microbiota, insulin sensitivity, and glucose tolerance. Novel therapeutic ...
  82. [82]
    Gut Microbiota Modulation in Type 2 Diabetes and Cardiometabolic ...
    Sep 10, 2025 · The review analyzed studies looking at the effects of probiotics, prebiotics, high-fiber diets, and fecal microbiota transplantation (FMT) on ...
  83. [83]
    [PDF] IDF Global Clinical Practice Recommendations for Managing Type 2 ...
    On behalf of the International Diabetes. Federation (IDF), it is my great pleasure to present this 2025 edition of the IDF Global Clinical Practice.
  84. [84]
    Global Survey: Government Policies on Diabetes in Schools - IDF Kids
    Mar 12, 2025 · Explore insights from a global survey on how government policies support diabetes care and education in schools around the world.
  85. [85]
    Position of SGLT2i in prediabetes: A systematic review of literature
    The US FDA has approved four major SGLT2i drugs – canagliflozin (2013), dapagliflozin (2014), empagliflozin (2014), and ertugliflozin (2017). 39 Sodium ...